✦ LIBER ✦

Biochemical and molecular characterization of 18 patients with pyridoxine-dependent epilepsy and mutations of the antiquitin (ALDH7A1) gene

✍ Scribed by Barbara Plecko; Karl Paul; Eduard Paschke; Sylvia Stoeckler-Ipsiroglu; Eduard Struys; Cornelis Jakobs; Hans Hartmann; Thomas Luecke; Matteo di Capua; Christoph Korenke; Christiane Hikel; Elke Reutershahn; Michael Freilinger; Fritz Baumeister; Friedrich Bosch; Wolfgang Erwa

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 299 KB
Volume: 28
Category: Article
ISSN: 1059-7794
DOI: 10.1002/humu.20433

No coin nor oath required. For personal study only.

✦ Synopsis

Communicated by Arnold Munnich

Patients with pyridoxine dependent epilepsy (PDE) present with early-onset seizures resistant to common anticonvulsants. According to the benefit of pyridoxine (vitamin B 6 ) and recurrence of seizures on pyridoxine withdrawal, patients so far have been classified as having definite, probable, or possible PDE. Recently, PDE has been shown to be caused by a defect of a-amino adipic semialdehyde (AASA) dehydrogenase (antiquitin) in the cerebral lysine degradation pathway. The accumulating compound piperideine-6-carboxylic acid (P6C) was shown to inactivate pyridoxalphosphate (PLP) by a Knoevenagel condensation. Pipecolic acid (PA) and AASA are markedly elevated in urine, plasma, and cerebrospinal fluid (CSF) and thus can be used as biomarkers of the disease. We have investigated 18 patients with neonatal seizure onset, who have been classified as having definite (11), probable (four), or possible (three) PDE. All patients had elevated PA and AASA in plasma (and urine) while on treatment with individual dosages of pyridoxine. Within this cohort, molecular analysis identified 10 novel mutations (six missense mutations, one nonsense mutation, two splice site mutations) within highly conserved regions of the antiquitin gene. Seven mutations were located in exonic sequences and two in introns 7 and 17. Furthermore, a novel deletion of exon 7 was identified. Two of the 36 alleles investigated require further investigation. A known mutation (p.Glu399Gln) was found with marked prevalence, accounting for 12 out of 36 alleles (33%) within our cohort. Pyridoxine withdrawal is no longer needed to establish the diagnosis of ''definite'' PDE. Administration of pyridoxine in PDE may not only correct secondary PLP deficiency, but may also lead to a reduction of AASA (and P6C) as presumably toxic compounds.

📜 SIMILAR VOLUMES

Mutational spectrum of the succinate sem

Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency

✍ Shinjiro Akaboshi; Boris M. Hogema; Andrea Novelletto; Patrizia Malaspina; Gajja 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB

Succinate semialdehyde dehydrogenase (SSADH; ALDH5A1) deficiency, a rare metabolic disorder that disrupts the normal degradation of GABA, gives rise to a highly heterogeneous neurological phenotype ranging from mild to very severe. The nature of the mutation has so far been reported in patients from

Characterization of mutations in the gen

Characterization of mutations in the gene doublecortin in patients with double cortex syndrome

✍ Joseph G. Gleeson; Sharon R. Minnerath; Jeremy W. Fox; Kristina M. Allen; Robert 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 402 KB 👁 2 views

Identification and molecular characteriz

Identification and molecular characterization of six novel mutations in the UDP-N-acetylglucosamine-1-phosphotransferase gamma subunit (GNPTG) gene in patients with mucolipidosis III gamma

✍ Emanuele Persichetti; Nadia A. Chuzhanova; Andrea Dardis; Barbara Tappino; Sandr 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB 👁 1 views

Mucolipidosis type III (MLIII) is an autosomal recessive disorder affecting lysosomal hydrolase trafficking. In a study of 10 patients from seven families with a clinical phenotype and enzymatic diagnosis of MLIII, six novel GNPTG gene mutations were identified. These included missense (p.T286M) and

Characterization of six novel mutations

Characterization of six novel mutations in the methylenetetrahydrofolate reductase (MTHFR) gene in patients with homocystinuria

✍ Sahar Sibani; Benedicte Christensen; Erin O'Ferrall; Irfan Saadi; François Hiou- 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 257 KB 👁 2 views

## Communicated by Mark Paalman Severe deficiency of methylenetetrahydrofolate reductase (MTHFR) is the most common inborn error of folate metabolism. Patients are characterized by severe hyperhomocysteinemia, homocystinuria and a variety of neurological and vascular problems. Eighteen rare mutatio

Clinical and molecular cytogenetic chara

Clinical and molecular cytogenetic characterization of two patients with non-mutational aberrations of the FMR2 gene

✍ Shozo Honda; Shin Hayashi; Mitsuhiro Kato; Yo Niida; Kiyoshi Hayasaka; Torayuki 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 261 KB 👁 1 views

Molecular analysis of the hydroxymethylb

Molecular analysis of the hydroxymethylbilane synthase (HMBS) gene in Italian patients with acute intermittent porphyria: Report of four novel mutations

✍ Franco Martinez di Montemuros; Elena Di Pierro; Silvia Fargion; Gianfranco Biolc 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 55 KB 👁 2 views

Acute intermittent porphyria (AIP) is an autosomal disorder caused by molecular abnormalities in the hydroxymethylbilane synthase (HMBS) gene coding for the third enzyme in the heme biosynthetic pathway. So far, more than 160 different mutations responsible for AIP have been identified in this gene.